natgillin/translations-raw huggingface dataset:
Thalidomide must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or drug reaction with eosinophilia and systemic symptoms (DRESS) is suspected and should not be resumed following discontinuation for these reactions. 
Talidomid je treba ukiniti pri angioedemu, izpuščaju 4. stopnje, eksfoliativnem ali buloznem izpuščaju in pri sumu na Stevens-Johnsonov sindrom (SJS), toksično epidermalno nekrolizo (TEN) ali reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS) in ga po ukinitvi zaradi teh reakcij ne smemo spet začeti dajati.
• The need for effective contraception 
• opozorilo, da je potrebna zanesljiva kontracepcija
Multiple myeloma generally cannot be cured. 
Načeloma diseminiranega plazmocitoma ni mogoče ozdraviti.
You must use one effective method of contraception if you are a woman who is able to become pregnant (see section 2, “What you need to know before you take Thalidomide Celgene”). 
Če lahko zanosite, morate uporabljati zanesljivo kontracepcijsko metodo (glejte poglavje 2 „Kaj morate vedeti, preden boste vzeli zdravilo Thalidomide Celgene“).
• you have a fall in the number of white blood cells (neutropenia) accompanied by fever and infection. 
• imate zmanjšano število belih krvničk (nevtropenijo), ki ga spremljata povišana telesna temperatura in okužba;
White opaque capsules marked “Thalidomide Celgene 50 mg”. 
Kapsule, motno bele barve, z oznako „Thalidomide Celgene 50 mg“.
There is no relevant use of Thalidomide Celgene in the paediatric population in the indication of multiple myeloma. 
Zdravilo Thalidomide Celgene ni primerno za uporabo pri pediatrični populaciji za indikacijo diseminirani plazmocitom.
• Ovulation inhibitory progesterone-only pills (i.e. desogestrel) 
• tablete, ki zavirajo ovulacijo in vsebujejo samo progesteron (tj. dezogestrel)
OR < 100,000 but 
ALI < 100.000, vendar ≥ 50.000
Hard capsule. 
FARMACEVTSKA OBLIKA trda kapsula
As thalidomide is found in semen, as a precaution all male patients must use condoms during treatment, during dose interruption and for at least 7 days following discontinuation of treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential who is not using effective contraception. 
Ker je talidomid prisoten v spermi, morajo vsi moški bolniki iz previdnosti uporabljati kondome med zdravljenjem, med prekinitvijo odmerjanja in še vsaj 7 dni po ukinitvi zdravljenja ob spolnih odnosih z nosečnico ali z žensko v rodni dobi in ne uporablja zanesljive kontracepcije.
Table 3: Adverse drug reactions (ADRs) reported in pivotal clinical study with thalidomide in combination with melphalan and prednisone and from post marketing use 
Preglednica 3: Neželeni učinki, o katerih so poročali v ključni klinični študiji za talidomid v kombinaciji z melfalanom in prednizonom ter med uporabo po začetku trženja
The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema. 
Najbolj pogosto opaženi neželeni učinki, povezani z uporabo talidomida v kombinaciji z melfalanom in prednizonom, so: nevtropenija, levkopenija, zaprtje, somnolenca, parestezija, periferna nevropatija, anemija, limfopenija, trombocitopenija, vrtoglavica, disestezija, tremor in periferni edem.
• A spinning feeling in your head, making it difficult to stand up and move normally. 
• vrtoglavica, težave pri stanju pokonci in normalnem premikanju,
In addition, you must not become pregnant while taking Thalidomide Celgene. 
Poleg tega med jemanjem zdravila Thalidomide Celgene ne smete zanositi.
Allergic reactions (hypersensitivity, angioedema, urticaria) 
Bolezni imunskega sistema neznana pogostnost alergijske reakcije (preobčutljivost, angioedem, urtikarija) †
• Adverse reaction reporting forms 
• Obrazce za poročanje neželenih učinkov
Patients should be monitored and dose reduction may be required. 
Bolnike je treba spremljati in jim po potrebi prilagoditi odmerek.
• That he should return the capsules to the pharmacist at the end of treatment 
• ob koncu zdravljenja mora preostale kapsule vrniti farmacevtu
• You must not donate semen: o during treatment o for at least 7 days after stopping treatment 
• Ne smete darovati sperme: o med zdravljenjem o še vsaj 7 dni po koncu zdravljenja
Grade 4 (neuropathy which is disabling) 
4. stopnja (nevropatija, ki bolnika onesposobi) Ukinite zdravljenje.
• That if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom 
• če partnerica zanosi, mora o tem takoj obvestiti zdravnika, ki ga zdravi, in vedno uporabljati kondom
• A fall in the number of white blood cells (neutropenia) accompanied by fever and infection. 
• padec števila belih krvničk (nevtropenija), ki ga spremljata povišana telesna temperatura in okužba,
• Tubal sterilisation 
• sterilizacija jajcevodov
• That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a woman with childbearing potential not on effective contraception 
• opozorilo, da je talidomid prisoten v spermi in o potrebi zaščite s kondomom, če je spolna partnerica noseča ali v rodni dobi in ne uporablja zanesljive kontracepcije
• Treatment initiation forms and/or equivalent tool for male patients should also include: o Confirmation that the physician has discussed the following: 
• Obrazci za začetek zdravljenja in/ali ustrezno orodje za moške bolnike morajo vsebovati tudi naslednje elemente: o Potrdilo, da se je zdravnik pogovoril o naslednjem:
There is no specific antidote for a thalidomide overdose. 
Za prevelik odmerek talidomida ni posebnega antidota.
Myocardial infarction 
Miokardni infarkt
The patient should continue anticoagulation therapy during the course of thalidomide treatment. 
Med zdravljenjem s talidomidom naj bolnik nadaljuje z antikoagulacijsko terapijo.
Use only as directed by your doctor. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Uporabljajte le po navodilih zdravnika.
* WHO Criteria 
* Kriteriji Svetovne zdravstvene organizacije
• Need to tell treating doctor immediately upon suspicion of pregnancy o Safety advice for men 
• opozorilo, da je treba v primeru suma na nosečnost, o tem nemudoma obvestiti zdravnika, ki vodi zdravljenje o varnostne nasvete za moške
SUMMARY OF PRODUCT CHARACTERISTICS 
PRILOGA I POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
• Inflammation and swelling of the tubes in your lungs (bronchitis). 
• vnetje in zatekanje pljučnih žil (bronhitis),
• The need for pregnancy tests i.e. before treatment, at least every 4 weeks during treatment and at least 4 weeks after treatment 
• potreba po testih nosečnosti, in sicer pred zdravljenjem, vsaj vsake 4 tedne med samim zdravljenjem in vsaj 4 tedne po zdravljenju
Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) AML and MDS were reported in one clinical study in patients with previously untreated multiple myeloma receiving the combination of melphalan, prednisone, and thalidomide (see section 4.4). 
Akutna mieloična levkemija (AML) in mielodisplastični sindromi (MDS) V klinični študiji so poročali o AML in MDS pri bolnikih s predhodno nezdravljenim disemininiranim plazmocitomom, ki so prejemali kombinacijo melfalana, prednizona in talidomida (glejte poglavje 4.4).
If pregnancy occurs in a woman treated with thalidomide, treatment must be stopped immediately and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice. 
Če ženska, ki se zdravi s talidomidom, zanosi, je treba zdravljenje nemudoma ustaviti in bolnico napotiti k zdravniku specialistu za teratologijo ali k zdravniku z izkušnjami v teratologiji, da oceni stanje in bolnici ustrezno svetuje.
Myocardial infarction (MI) has been reported in patients receiving thalidomide, particularly in those with known risk factors. 
Pri bolnikih, zlasti pri tistih z znanimi dejavniki tveganja, ki so prejemali talidomid, so poročali o miokardnem infarktu (MI).
• She understands the need for effective contraception, without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and at least 4 weeks after the end of treatment 
• Bolnica razume potrebo po zanesljivi kontracepciji brez prekinitev, vsaj 4 tedne pred pričetkom zdravljenja, med celotnim trajanjem zdravljenja ter vsaj 4 tedne po koncu zdravljenja.
• The need for effective contraception, without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and at least 4 weeks after the end of treatment 
• potrebna je zanesljiva kontracepcija brez prekinitev, vsaj 4 tedne pred pričetkom zdravljenja, med celotnim trajanjem zdravljenja ter vsaj 4 tedne po koncu zdravljenja
There is minimal cytochrome P450 catalysed hepatic metabolism of thalidomide. 
Obstaja minimalna jetrna presnova talidomida, katalizirana s citokromom P450.
The benefit achieved with thalidomide and the risk of AML and MDS must be taken into account before initiating treatment with thalidomide in combination with melphalan and prednisone. 
Pred uvedbo zdravljenja s talidomidom v kombinaciji z melfalanom in prednizonom je treba upoštevati oboje, koristi talidomida in tveganje AML in MDS.
• Bleeding from the stomach or bowels (gastrointestinal haemorrhage). 
• krvavitev iz želodca ali črevesa (krvavitev prebavil),
2 D bar code carrying the unique identifier 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
Prednisone dosed once daily on Days 1 to 4 of each 42-day cycle. 
f Prednizon se daje enkrat na dan od 1. do 4. dne vsakega 42-dnevnega cikla.
• Treatment initiation forms and/or equivalent tool for women with no childbearing potential should also include: o Confirmation that the physician has discussed the following: 
• Obrazci za začetek zdravljenja in/ali ustrezno orodje za ženske, ki niso v rodni dobi, morajo vsebovati tudi: o Potrdilo, da se je zdravnik pogovoril o naslednjem:
Table 2: Recommended dose modifications for thalidomide -related neuropathy in first line treatment of multiple myeloma 
Preglednica 2: Priporočene spremembe odmerkov za nevropatijo, povezano s talidomidom, za primarno zdravljenje diseminiranega plazmocitoma Resnost nevropatije
Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) A statistically significant increase of AML and MDS was observed in one clinical study in patients with previously untreated MM receiving the combination of melphalan, prednisone, and thalidomide (MPT). 
Akutna mieloična levkemija (AML) in mielodisplastični sindromi (MDS) V klinični študiji so pri bolnikih s predhodno nezdravljenim diseminiranim plazmocitomom, ki so prejemali kombinacijo melfalana, prednizona in talidomida (MPT), opazili statistično pomembno povečanje AML in MDS.
It is important to note that a small number of patients with multiple myeloma may develop additional types of cancer, especially haematological malignancies, and it is possible that this risk may be increased with Thalidomide Celgene treatment; therefore your doctor should carefully evaluate the benefit and risk when you are prescribed Thalidomide Celgene. 
Pomembno je omeniti, da se lahko pri majhnem številu bolnikov z diseminiranim plazmocitomom razvijejo dodatne vrste raka, zlasti hematološke malignosti.
Particularly, a haemoglobin concentration above 12g/dl should lead to discontinuation of erythropoietic agents. 
Posebej pomembno je ukiniti zdravljenje z eritropoetskimi zdravili, če se koncentracija hemoglobina dvigne nad 12 g/dl.
Thalidomide causes birth defects and foetal death. 
Talidomid povzroča prirojene okvare in smrt zarodka.
Myelodysplastic syndrome* 
občasni mielodisplastični sindrom*,^
If pregnancy occurs in a partner of a male patient taking thalidomide, the female partner should be referred to a physician specialised or experienced in teratology for evaluation and advice. 
Če partnerica moškega, ki jemlje talidomid, zanosi, jo je treba napotiti k zdravniku specialistu za teratologijo ali zdravniku z izkušnjami v teratologiji, da oceni stanje in bolnici ustrezno svetuje.
Dose delay, reduction or discontinuation, dependent upon the NCI CTC (National Cancer Institute Common Toxicity Criteria) grade, may be necessary. 
Glede na stopnjo toksičnosti po splošnih merilih Nacionalnega inštituta za raka (NCI CTC - National Cancer Institute Common Toxicity Criteria) bo morda potrebna odložitev, zmanjšanje odmerka ali ukinitev zdravljenja.
Patients with severe organ impairment should be carefully monitored for adverse reactions. 
Posebnih priporočil o odmerkih za to skupino bolnikov ni. Bolnike s hudo okvaro organov je treba skrbno spremljati v zvezi z neželenimi učinki.
• Obligations of healthcare professionals who intend to prescribe or dispense Thalidomide Celgene including o The need to provide comprehensive advice and counselling to patients o That patients should be capable of complying with the requirements for the safe use of thalidomide o Need to provide patients with the appropriate patient educational material o Report any pregnancy, or adverse events to Celgene and the local health authority (if applicable to a Member State) using the forms provided in the “Educational Healthcare Professional's Kit” 
• Obveznosti zdravstvenih delavcev, ki nameravajo predpisovati ali izdajati zdravilo Thalidomide Celgene, kar vključuje: o obveznost izčrpnega svetovanja bolnikom, o bolniki morajo biti sposobni izpolnjevati zahteve za varno uporabo talidomida, o bolnikom je treba izročiti ustrezna izobraževalna gradiva,
Cases of allergic reactions/angioedema and serious cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of Thalidomide. 
Pri uporabi talidomida so poročali o primerih alergijskih reakcij/angioedema in resnih reakcijah na koži, vključno s Stevens-Johnsonovim sindromom (SJS), toksično epidermalno nekrolizo (TEN) in reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu, kjer so na voljo tudi povezave do drugih spletnih strani o redkih boleznih in zdravljenju.
• Fever, feeling generally unwell. 
• povišana telesna temperatura, splošno slabo počutje,
• That if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom during intercourse 
• opozorilo, da je treba v primeru zanositve partnerice nemudoma obvestiti zdravnika, ki vodi zdravljenje, in med odnosom vedno uporabljati kondom
• Treatment initiation forms and/or equivalent tool for women of childbearing potential should also include: o Confirmation that the physician has discussed the following: 
• Obrazci za začetek zdravljenja in/ali ustrezno orodje za ženske v rodni dobi morajo vsebovati tudi naslednje elemente: o Potrdilo, da se je zdravnik pogovoril o naslednjem:
Always take Thalidomide Celgene exactly as your doctor or pharmacist has told you to. 
Pri jemanju zdravila Thalidomide Celgene natančno upoštevajte navodila zdravnika ali farmacevta.
Haematological disorders 
Hematološke bolezni
• Swelling of hands and feet. 
• zatekanje rok in nog,
An increased incidence of second primary malignancies (SPM) has also been observed in patients with newly diagnosed MM receiving lenalidomide. 
Pri bolnikih z novo diagnosticiranim disemniniranim plazmocitomom, ki so prejemali lenalidomid, so opazili tudi zvišano incidenco drugih primarnih malignosti.
• The need for pregnancy tests i.e. before treatment, at least every 4 weeks during treatment and after treatment 
• potrebno je izvesti teste nosečnosti pred zdravljenjem, vsaj vsake 4 tedne med zdravljenjem in po zdravljenju
As such the metabolism of thalidomide is not expected to be affected by hepatic or renal dysfunction. 
Ne pričakuje se, da bi jetrna ali ledvična disfunkcija vplivala na presnovo talidomida.
All unused capsules should be returned to the pharmacist at the end of treatment. 
Po koncu zdravljenja je treba vse neuporabljene kapsule vrniti farmacevtu.
Somnolence 
Somnolenca
Pulmonary embolism*, Interstitial lung disease, Bronchopneumopathy, Dyspnea 
Bolezni dihal, prsnega koša in mediastinalnega prostora pogosti pljučna embolija*, intersticijska pljučna bolezen, bronhopnevmopatija, dispneja neznana pogostnost pljučna hipertenzija†
• That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a woman with childbearing potential not using effective contraception 
• talidomid je prisoten v spermi, zato mora pri spolni partnerici, ki je noseča ali v rodni dobi in ne uporablja zanesljive kontracepcije, uporabiti kondom
Thalidomide must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS, TEN or DRESS is suspected, and should not be resumed following discontinuation for these reactions. 
Talidomid je treba ukiniti pri angioedemu, izpuščaju 4. stopnje, eksfoliativnem ali buloznem izpuščaju in pri sumu na SJS, TEN ali DRESS in ga po ukinitvi zaradi teh reakcij ne smemo spet začeti dajati (glejte poglavji 4.2 in 4.8).
Patients treated with thalidomide have an increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event) (see section 4.8). 
Pri bolnikih, ki so se zdravili s talidomidom, je tveganje za vensko trombembolijo (kot sta globoka venska tromboza in pljučna embolija) večje (glejte poglavje 4.8).
Platelet Count (/µL) 
Število trombocitov (/µl)
NAME OF THE MARKETING AUTHORISATION HOLDER 
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
How to take Thalidomide Celgene 
Kako jemati zdravilo Thalidomide Celgene
• Blurred vision. 
• zamegljen vid,
Adverse reactions from post-marketing experience such as febrile neutropenia and pancytopenia were reported with thalidomide. 
Pri talidomidu so poročali o neželenih učinkih v okviru izkušenj v obdobju trženja, kot sta febrilna nevtropenija in pancitopenija.
Patients should be monitored for syncope, bradycardia and atrioventricular block; dose reduction or discontinuation may be required. 
Sinkopa, bradikardija in atrioventrikularni blok Bolnike je treba spremljati za sinkopo, bradikardijo in atrioventrikularni blok.
Thalidomide Celgene 50 mg thalidomide 
IME ZDRAVILA Thalidomide Celgene 50 mg talidomid
• Hearing decreased or deafness. 
• poslabšanje sluha ali gluhost,
Thalidomide Celgene 50 mg hard capsules thalidomide 
Thalidomide Celgene 50 mg trde kapsule talidomid
Patients should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of thalidomide. 
Bolniki med zdravljenjem (vključno med prekinitvijo odmerjanja) in še vsaj 7 dni po ukinitvi zdravljenja s talidomidom ne smejo darovati krvi.
Most patients taking thalidomide can be expected to experience adverse reactions. 
Pričakuje se, da se bodo neželeni učinki pojavili pri večini bolnikov, ki jemljejo talidomid.
Toxic skin eruption, Rash, Dry skin 
Bolezni kože in podkožja občasni toksični kožni izpuščaj, izpuščaj, suha koža neznana pogostnost
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI Neuporabljeno zdravilo morate vrniti farmacevtu.
Deep vein thrombosis* 
Žilne bolezni pogosti globoka venska tromboza*
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ Ime in naslov izdelovalcev, odgovornih za sproščanje serij Celgene Distribution B.V.
Dose delay, reduction or discontinuation, dependent upon the NCI CTC grade, may be necessary. 
Glede na stopnjo NCI CTC bo morda potrebna odložitev, zmanjšanje odmerka ali ukinitev zdravljenja.
Male patients should not donate semen or sperm during treatment (including during dose interruptions) and for at least 7 days following discontinuation of thalidomide. 
Moški bolniki med zdravljenjem (vključno med prekinitvijo odmerjanja) in še vsaj 7 dni po ukinitvi zdravljenja s talidomidom ne smejo darovati semenčic ali sperme.
The distribution of thalidomide is not influenced by age, gender, renal function and blood chemistry variables, to any significant level. 
Starost, spol, delovanje ledvic in parametri biokemičnih krvnih preiskav nimajo pomembnega vpliva na porazdelitev talidomida.
Hearing impaired or deafness 
Okvara jeter in ledvic
Thalidomide Celgene 50 mg hard capsules 
IME ZDRAVILA Thalidomide Celgene 50 mg trde kapsule
What Thalidomide Celgene is 
Thalidomide Celgene.
Thalidomide Celgene 50 mg 
PODATKI V BRAILLOVI PISAVI Thalidomide Celgene 50 mg
Do not use if you notice any damage or signs of tampering. 
Ne uporabljajte tega zdravila, če opazite poškodbe ali znake odpiranja.
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking this medicine in the following situations: 
Pred začetkom jemanja zdravila Thalidomide Celgene se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro v naslednjih primerih:
• That he should not donate semen during treatment (including during dose interruptions) and for at least 7 days following discontinuation of thalidomide 
• opozorilo, da med zdravljenjem (tudi v obdobju med prekinitvijo odmerjanja) in še vsaj 7 dni po koncu zdravljenja ne sme darovati sperme
Reporting of side effects 
Okrepitev sedativnih učinkov drugih zdravil
Hepatic and renal impairment 
Srčne in žilne bolezni
• Implant 
• vsadek
• The need to stop thalidomide immediately upon suspicion of pregnancy 
• opozorilo, da je v primeru suma na nosečnost treba takoj ustaviti zdravljenje s talidomidom
6.6 Special precautions for disposal and other handling 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Kapsul ne odpirajte in ne drobite.
Cases of pulmonary hypertension, some fatal, have been reported in patients treated with thalidomide. 
Pri bolnikih, zdravljenih s talidomidom, so poročali o primerih pljučne hipertenzije, ki se je včasih končala s smrtjo.
• Need to stop thalidomide immediately upon suspicion of pregnancy 
• takoj po sumu na nosečnost mora prenehati uporabljati talidomid
METHOD AND ROUTE(S) OF ADMINISTRATION 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za peroralno uporabo.
Neutropenia, Leukopenia, Anaemia, Lymphopenia, Thrombocytopenia 
Bolezni krvi in limfatičnega sistema zelo pogosti nevtropenija, levkopenija, anemija, limfopenija, trombocitopenija pogosti febrilna nevtropenija†, pancitopenija†
WALLET CARD 
ŠTEVILKA SERIJE Lot
Serious cutaneous reactions including Stevens-Johnson syndrome TEN and DRESS have been reported with the use of thalidomide therapy. 
Pri zdravljenju s talidomidom so poročali o hudih kožnih reakcijah, vključno s Stevens-Johnsonovim sindromom, TEN in DRESS.
If thalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water. 
V primeru stika talidomida s sluznico jo morate temeljito sprati z obilico vode.
• Take this medicine by mouth. 
• Zdravilo se uporablja peroralno.
Thrombocytopenia, including grade 3 or 4 adverse reactions, has been reported in multiple myeloma patients receiving MPT. 
Pri bolnikih z diseminiranim plazmocitomom, ki so prejemali MPT, so poročali o trombocitopeniji, vključno z neželenimi učinki 3. ali 4. stopnje.
Other medicines and Thalidomide Celgene 
Shranjevanje zdravila Thalidomide Celgene